Start here
The Signal, in Five Charts
One argument, five charts: how precision-medicine technologies move from scientific novelty to clinical infrastructure — and why that arc decides where value lands in the tools and diagnostics layer. Each chart is a doorway to a deeper analysis; follow the links to go further.
The market
The center of gravity has moved
Since 2019 the tools-and-diagnostics market has passed through distinct eras — from NicheOmics toward the emerging ClinOmics, where clinical demand, not research, drives the spend.
NicheOmics
Under the radar
SwabRush
Diagnostics to the rescue
GenomicWinter
The reckoning
LiquidLift
Liquid biopsy leads
MarginOmics
Specialty Dx catches up
ClinOmics →
Clinical pull drives tool spend
Adoption
Where each technology sits
Eight technologies placed on the Rogers adoption curve every year, read from ~200,000 publications and calibrated against reality. The discovery platforms march the same path; cfDNA and NGS are further along.
| Technology | ’06 | ’07 | ’08 | ’09 | ’10 | ’11 | ’12 | ’13 | ’14 | ’15 | ’16 | ’17 | ’18 | ’19 | ’20 | ’21 | ’22 | ’23 | ’24 | ’25 | ’26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NGS | |||||||||||||||||||||
| scRNA-seq | |||||||||||||||||||||
| Spatial Tx | |||||||||||||||||||||
| Long-read | |||||||||||||||||||||
| Spatial Proteo | |||||||||||||||||||||
| cfDNA | |||||||||||||||||||||
| Multi-omics | |||||||||||||||||||||
| Hi-Plex M-O |
“Late Majority” and “Laggards” are Rogers’ terms for a saturated, standard-infrastructure stage — the remaining non-adopters in a now-ubiquitous technology, not a declining or failing one. NGS sits here precisely because it has become routine.
Faded cells = 2026 (partial year, annualized — provisional). Click any cell for detail.
The synthesis
Scientific push vs. clinical pull
Plot scientific momentum against clinical pull and the field sorts itself: cfDNA broke through, NGS became infrastructure, and the six hottest discovery platforms sit in the translation gap — science racing ahead of the clinic.
Bubble size = 2025 publication volume. X = recent publication growth (the adoption model’s median 1/3/5-yr CAGR); the divider is the literature’s ~4%/yr ambient growth. Y = share of 2023–2025 papers in clinical/medical journals (Scimago clinical subject categories), a journal-discipline proxy for clinical translation. Validated against the AI application classifier where available — NGS 42% vs 45%, cfDNA 64% vs 85%, the discovery platforms ~30% vs ~18%: the absolute values differ but the ranking and quadrant placement agree. Dividers are illustrative. This is scholarly translation, not commercial adoption.
Into the clinic
From research tool to clinical infrastructure
NGS is the completed precedent. The share of NGS papers doing clinical and diagnostic work climbed from under 10% to roughly half — the research-to-clinic transition every other platform is now walking.
The payoff
The literature leads the market
The reason any of this matters commercially: the scholarly signal runs a few years ahead of the dollars. By the same clinical share, publications (49%) and NGS manufacturer revenue (~51%) have converged — and the publication curve got there first.
And in real time
The clinical pipeline
Where clinical pull shows up first: assays entering trials, MRD pushing into solid tumors, ctDNA nearing standard of care, and the population-scale MCED bet. These refresh live from ClinicalTrials.gov.